Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
SC 13G/A An amendment to the SC 13G filing View HTML
0001193125-17-040526.pdf
0001193125-17-040526.rtf
0001193125-17-040526.xls
4 Statement of changes in beneficial ownership of securities View HTML
0000899243-17-003295.pdf
0000899243-17-003295.rtf
0000899243-17-003295.xls
4 Statement of changes in beneficial ownership of securities View HTML
0000899243-17-003297.pdf
0000899243-17-003297.rtf
0000899243-17-003297.xls
SC 13G A statement of beneficial ownership of common stock by certain persons View HTML
0000215457-17-002178.pdf
0000215457-17-002178.rtf
8-K Report of unscheduled material events or corporate event View HTML
0001558370-17-000061.pdf
0001558370-17-000061.rtf
0001558370-17-000061.xls
CT ORDER CT ORDER
9999999997-17-000052.pdf
4 Statement of changes in beneficial ownership of securities View HTML
0000899243-16-036208.pdf
0000899243-16-036208.rtf
0000899243-16-036208.xls
SC 13G A statement of beneficial ownership of common stock by certain persons View HTML
0001193805-16-004377.pdf
0001193805-16-004377.rtf
0001193805-16-004377.xls
424B5 Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3 View HTML
0001047469-16-017106.pdf
0001047469-16-017106.rtf
0001047469-16-017106.xls
8-K Report of unscheduled material events or corporate event View HTML
0001558370-16-010475.pdf
0001558370-16-010475.rtf
0001558370-16-010475.xls